Fulcrum Therapeutics, Inc.

Filed a patent for "macrocyclic azolopyridine derivatives as eed and prc2 modulators" on Thu, May 2, 2024

Filed a patent for "methods of treating facioscapulohumeral muscular dystrophy with losmapimod" on Wed, January 17, 2024

Filed a patent for "methods of treating facioscapulohumeral muscular dystrophy with losmapimod" on Fri, April 8, 2022

Filed a patent for "methods of treating facioscapulohumeral muscular dystrophy with losmapimod" on Mon, May 23, 2022